BLAINJECTIONINJECTABLEPriority Review
Approved
Nov 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
MEPSEVII (vestronidase alfa) by Ultragenyx Pharmaceutical is (mps vii or sly syndrome) is a lysosomal disorder characterized by the deficiency of gus that results in gag accumulation in cells throughout the body leading to multisystem tissue and organ damage. Approved for sly syndrome). First approved in 2017.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEPSEVII (vestronidase alfa) is a recombinant human glucuronidase (GUS) enzyme replacement therapy for mucopolysaccharidosis type VII (MPS VII or Sly syndrome), a rare lysosomal storage disorder. It works by providing exogenous GUS enzyme that is taken up into cellular lysosomes via mannose-6-phosphate receptors, enabling catabolism of accumulated glycosaminoglycans (GAGs) in affected tissues. The drug targets the multisystem tissue and organ damage caused by GUS deficiency.
Peak
Peak lifecycle suggests stable commercial operations with mature field infrastructure; 23 linked jobs indicate sustained team investment.
Mechanism of Action
(MPS VII or Sly syndrome) is a lysosomal disorder characterized by the deficiency of GUS that results in GAG accumulation in cells throughout the body leading to multisystem tissue and organ damage. Vestronidase alfa-vjbk is a recombinant form of human GUS and is intended to provide exogenous GUS…
Pharmacologic Class:
Lysosomal beta Glucuronidase
Indications (1)
Clinical Trials (1)
Expanded Access to Mepsevii
MPS VIIMucopolysaccharidosis VIISly Syndrome
Worked on MEPSEVII at Ultragenyx Pharmaceutical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.